Work

Abstract 462: TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of solid tumors with MTAP loss

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-462

Authors: Kimberly J. Briggs, Alice Tsai, Minjie Zhang, Wenhai Zhang, Alan Huang, Jannik N. Andersen, Kevin M. Cottrell

Institution: Tango Therapeutics (United States)

Language: English

Topic: Cancer-related gene regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409691038

Cites:

Cited by: 4

Related to: 10